Often that's the case DOB, but not in this one - its a [less]...

Often that's the case DOB, but not in this one - its a [less] simple case of rights, default, and possible default. There are too many that had/have unrealistic expectations on Approval overheads and the flow on to R&D time and costs. None-the-less it is something to be worked throug now, while I hold out on a slim chance that an at the door settlement will be reached. I have been in the bio sector for a long time now and consider my expectations realistic. I saying that I every faith in the products SLA and BPO are to ramp into production and full commercialisation shortly - not trader shortly - Bio shortly.